www.bioscience.co.uk
Sales & Support: +44 (0)1223 316 855

*

Firefly Luciferase CD19 Knockout NALM6 Cell Line

Catalogue number:
Supplier:
Size:
2 vials
Product is available in:
  • UK
  • Ireland
  • Europe
  • USA
  • Rest of World
£5809.00 Shipping is calculated in checkout
Alternative Names:

B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12

Product Description:

Firefly Luciferase CD19 Knockout NALM6 Cell Line is a NALM6 cell line constitutively expressing Firefly (Photinus pyralis) luciferase under the control of a CMV promoter, in which CD19 (Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) has been genetically removed using CRISPR/Cas9 genome editing using a lentivirus encoding CRISPR/Cas9 gene and sgRNA (single guide RNA) targeting human CD19. This product is for research use only and is subject to a Limited Use License. For your order to be processed, you will be required to complete a Limited Use License Agreement form at: https://bpsbioscience.com/license/agreement/form, ensuring you state your Purchase Order number when asked for Sales Order/Quote #. Further information can be found at: https://bpsbioscience.com/license.